Long acting GLP-1 receptor agonist (injectable)
Semaglutide maximum tolerated dose injection once weekly
SEMA_SC_MTD_1p7-2p4_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -16.81 (-24.10 to -2.71) | 0.61 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.85 (0.24 to 2.99) | 0.59 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.36 (1.90 to 5.90) | 0.54 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 15.93 (5.42 to 51.65) | 0.11 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.63 (1.54 to 8.17) | 0.23 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.57 (1.25 to 10.01) | 0.28 |